Memantin Stada

Memantine Hydrochloride, the active ingredient in Memantin Stada, is an NMDA receptor antagonist presented as an oral tablet for oral use. It is indicated for the treatment of moderate to severe Alzheimer’s disease in adults.

GNH USA supplies Memantin Stada as a licensed, GDP-compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide.

Memantin Stada is an NMDA receptor antagonist used in the management of Alzheimer’s disease and related cognitive decline.

- Moderate to severe Alzheimer’s disease: Improves cognition and functional abilities in patients with moderate to severe disease. - Cognitive decline: Helps slow the progression of memory loss associated with Alzheimer’s. - Neuropsychiatric symptoms: May reduce agitation and aggression linked to Alzheimer’s disease.

Memantin Stada may be associated with a range of adverse reactions, which are categorized by frequency.

Common Side Effects: - Dizziness - Headache - Constipation - Confusion - Fatigue - Nausea

Serious or Rare Side Effects: - Seizures - Cardiac arrhythmia - Severe skin reactions (e.g., Stevens‑Johnson syndrome) - Hepatic injury - Hallucinations or psychosis - Suicidal thoughts or behavior

When prescribing Memantin Stada, clinicians should consider several safety factors.

- Renal impairment: Adjust dose or monitor renal function closely. - Hepatic impairment: Monitor liver enzymes and consider dose modification. - History of seizures: Use with caution and observe for increased seizure activity. - Concomitant NMDA agonists: Avoid co‑administration due to potential antagonistic effects. - Pregnancy and lactation: Safety not established; weigh benefits against potential risks. - Store at room temperature: Keep in the original container, protect from moisture and direct sunlight.

Memantin Stada can interact with other medicines, requiring attention to avoid adverse outcomes.

Major Interactions (Avoid): - Amantadine: Additive NMDA antagonism may increase CNS effects. - Ketamine: Combined use can potentiate neuro‑psychiatric adverse events. - Mannitol: May enhance oral absorption leading to higher plasma levels.

Moderate Interactions (Monitor Closely): - Anticholinergic agents: May diminish cognitive benefits of memantine. - Central nervous system depressants: Increased risk of sedation and dizziness. - Diuretics: Potential electrolyte disturbances that could affect tolerability.